Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
Cellular Oncology (Dordrecht, Netherlands)
|
December 20, 2022
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Nicholas Coupe, Lina Guo, Esther Bridges, et al.
Cancer Research
|
August 3, 2017
Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer
Zenobia D'Costa, Keaton Jones, Abul Azad, et al.
Oncotarget
|
January 22, 2015
Hypoxia induces a lipogenic cancer cell phenotype via HIF1α-dependent and -independent pathways
Alessandro Valli, Miguel Rodriguez, Loukas Moutsianas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 9, 2021
The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
Hagen Schwenzer, Erica De Zan, Mustafa Elshani, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
Cellular Oncology (Dordrecht, Netherlands)
|
December 20, 2022
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Nicholas Coupe, Lina Guo, Esther Bridges, et al.
Cancer Research
|
August 3, 2017
Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer
Zenobia D'Costa, Keaton Jones, Abul Azad, et al.
Oncotarget
|
January 22, 2015
Hypoxia induces a lipogenic cancer cell phenotype via HIF1α-dependent and -independent pathways
Alessandro Valli, Miguel Rodriguez, Loukas Moutsianas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 9, 2021
The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
Hagen Schwenzer, Erica De Zan, Mustafa Elshani, et al.
Page
of 2